Oct. 17, 2023

An article by the Associated Press (AP) published Oct. 17 considers, “Are 3D mammograms better than standard 2D imaging for catching advanced [breast] cancers?” The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), discussed in the article and managed daily by the American College of Radiology® (ACR®) Center for Research and Innovation, intends to find out.

The National Cancer Institute-funded TMIST study — one of the most diverse cancer screening trials in history — already has nearly 93,000 of the planned 128,000 participants enrolled. The AP reports, “At the U.S. study sites, 21% of study participants are Black women — that’s higher than a typical cancer treatment study, in which 9% of participants are Black.”

The AP quotes Etta Pisano, MD, FACR, ACR Chief Research Officer, who shared that the study, led by the ECOG-ACRIN Cancer Research Group, “added more international sites to enhance the trial’s diversity, particularly for Hispanic and Asian women.”

For more information, visit acr.org/TMIST.


Related ACR News

  • ACR Commission Chair Participates in Congressional Panel

    The event aimed to educate congressional staff and lawmakers about the need to ensure all women have access to the full continuum of breast imaging care.

    Read more
  • State Legislative Update: Breast Health Legislation

    Specific topics include measures to eliminate patient cost sharing and repeal or revision of existing breast density notification.

    Read more
  • Coding Guides Updated for 2025

    The guides have been updated to include new, revised and deleted CPT® codes for 2025.

    Read more